Malignancy‐associated immune responses: Lessons from human inborn errors of immunity
Immunology · 2023-11 · 170 (3) · 319-333
DOI: 10.1111/imm.13675 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 19.06.2023. Verfasst von Agnel Aliyath und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Imperial College London, UK. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
It is widely understood that cancer is a significant cause of morbidity and mortality worldwide. Despite numerous available treatments, prognosis for many remains poor, thus, the development of novel therapies remains essential. Given the incredible success of many immunotherapies in this field, the important contribution of the immune system to the control, and elimination, of malignancy is clear. While many immunotherapies target higher‐order pathways, for example, through promoting T‐cell activation via immune checkpoint blockade, the potential to target specific immunological pathways is largely not well researched. Precisely understanding how immunity can be tailored to respond to specific challenges is an exciting idea with great potential, and may trigger the development of new therapies for cancer. Inborn Errors of Immunity (IEI) are a group of rare congenital disorders caused by gene mutations that result in immune dysregulation. This heterogeneous group, spanning widespread, multisystem immunopathology to specific immune cell defects, primarily manifest in immunodeficiency symptoms. Thus, these patients are particularly susceptible to life‐threatening infection, autoimmunity and malignancy, making IEI an especially complex group of diseases. While precise mechanisms of IEI‐induced malignancy have not yet been fully elucidated, analysis of these conditions can highlight the importance of particular genes, and downstream immune responses, in carcinogenesis and may help inform mechanisms which can be utilised in novel immunotherapies. In this review, we examine the links between IEIs and cancer, establishing potential connections between immune dysfunction and malignancy and suggesting roles for specific immunological mechanisms involved in preventing carcinogenesis, thus, guiding essential future research focused on cancer immunotherapy and providing valuable insight into the workings of the immune system in both health and disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Imperial College London, UK.
ORCID-Profile: Agnel Aliyath, Ayolola Eni-Olotu, Niamh Donaldson, Priyanka Trivedi
Zitieren
APA
Aliyath, A., Eni-Olotu, A., Donaldson, N., & Trivedi, P. (2023). Malignancy‐associated immune responses: Lessons from human inborn errors of immunity. Immunology, 170(3), 319-333. https://doi.org/10.1111/imm.13675
Vancouver
Aliyath A, Eni-Olotu A, Donaldson N, Trivedi P. Malignancy‐associated immune responses: Lessons from human inborn errors of immunity. Immunology. 2023;170(3):319-333. doi:10.1111/imm.13675
BibTeX
@article{Aliyath2023,
author = {Aliyath, Agnel and Eni-Olotu, Ayolola and Donaldson, Niamh and Trivedi, Priyanka},
title = {Malignancy‐associated immune responses: Lessons from human inborn errors of immunity},
journal = {Immunology},
year = {2023},
volume = {170},
number = {3},
pages = {319--333},
doi = {10.1111/imm.13675}
}
EUVIMED